BACKGROUND: Serum cystatin C was proposed as a potential replacement for serum creatinine in glomerular filtration rate (GFR) estimation. We report the development and evaluation of GFR-estimating equations using serum cystatin C alone and serum cystatin C, serum creatinine, or both with demographic variables. STUDY DESIGN: Test of diagnostic accuracy. SETTING & PARTICIPANTS: Participants screened for 3 chronic kidney disease (CKD) studies in the United States (n = 2,980) and a clinical population in Paris, France (n = 438). REFERENCE TEST: Measured GFR (mGFR). INDEX TEST: Estimated GFR using the 4 new equations based on serum cystatin C alone, serum cystatin C, serum creatinine, or both with age, sex, and race. New equations were developed by using linear regression with log GFR as the outcome in two thirds of data from US studies. Internal validation was performed in the remaining one third of data from US CKD studies; external validation was performed in the Paris study. MEASUREMENTS: GFR was measured by using urinary clearance of iodine-125-iothalamate in the US studies and chromium-51-EDTA in the Paris study. Serum cystatin C was measured by using Dade-Behring assay, standardized serum creatinine values were used. RESULTS: Mean mGFR, serum creatinine, and serum cystatin C values were 48 mL/min/1.73 m(2) (5th to 95th percentile, 15 to 95), 2.1 mg/dL, and 1.8 mg/L, respectively. For the new equations, coefficients for age, sex, and race were significant in the equation with serum cystatin C, but 2- to 4-fold smaller than in the equation with serum creatinine. Measures of performance in new equations were consistent across the development and internal and external validation data sets. Percentages of estimated GFR within 30% of mGFR for equations based on serum cystatin C alone, serum cystatin C, serum creatinine, or both levels with age, sex, and race were 81%, 83%, 85%, and 89%, respectively. The equation using serum cystatin C level alone yields estimates with small biases in age, sex, and race subgroups, which are improved in equations including these variables. LIMITATIONS: Study population composed mainly of patients with CKD. CONCLUSIONS: Serum cystatin C level alone provides GFR estimates that are nearly as accurate as serum creatinine level adjusted for age, sex, and race, thus providing an alternative GFR estimate that is not linked to muscle mass. An equation including serum cystatin C level in combination with serum creatinine level, age, sex, and race provides the most accurate estimates.
BACKGROUND: Serum cystatin C was proposed as a potential replacement for serum creatinine in glomerular filtration rate (GFR) estimation. We report the development and evaluation of GFR-estimating equations using serum cystatin C alone and serum cystatin C, serum creatinine, or both with demographic variables. STUDY DESIGN: Test of diagnostic accuracy. SETTING & PARTICIPANTS: Participants screened for 3 chronic kidney disease (CKD) studies in the United States (n = 2,980) and a clinical population in Paris, France (n = 438). REFERENCE TEST: Measured GFR (mGFR). INDEX TEST: Estimated GFR using the 4 new equations based on serum cystatin C alone, serum cystatin C, serum creatinine, or both with age, sex, and race. New equations were developed by using linear regression with log GFR as the outcome in two thirds of data from US studies. Internal validation was performed in the remaining one third of data from US CKD studies; external validation was performed in the Paris study. MEASUREMENTS: GFR was measured by using urinary clearance of iodine-125-iothalamate in the US studies and chromium-51-EDTA in the Paris study. Serum cystatin C was measured by using Dade-Behring assay, standardized serum creatinine values were used. RESULTS: Mean mGFR, serum creatinine, and serum cystatin C values were 48 mL/min/1.73 m(2) (5th to 95th percentile, 15 to 95), 2.1 mg/dL, and 1.8 mg/L, respectively. For the new equations, coefficients for age, sex, and race were significant in the equation with serum cystatin C, but 2- to 4-fold smaller than in the equation with serum creatinine. Measures of performance in new equations were consistent across the development and internal and external validation data sets. Percentages of estimated GFR within 30% of mGFR for equations based on serum cystatin C alone, serum cystatin C, serum creatinine, or both levels with age, sex, and race were 81%, 83%, 85%, and 89%, respectively. The equation using serum cystatin C level alone yields estimates with small biases in age, sex, and race subgroups, which are improved in equations including these variables. LIMITATIONS: Study population composed mainly of patients with CKD. CONCLUSIONS: Serum cystatin C level alone provides GFR estimates that are nearly as accurate as serum creatinine level adjusted for age, sex, and race, thus providing an alternative GFR estimate that is not linked to muscle mass. An equation including serum cystatin C level in combination with serum creatinine level, age, sex, and race provides the most accurate estimates.
Authors: L Manetti; E Pardini; M Genovesi; A Campomori; L Grasso; L L Morselli; I Lupi; G Pellegrini; L Bartalena; F Bogazzi; E Martino Journal: J Endocrinol Invest Date: 2005-04 Impact factor: 4.256
Authors: Linda F Fried; Ronit Katz; Mark J Sarnak; Michael G Shlipak; Paulo H M Chaves; Nancy Swords Jenny; Catherine Stehman-Breen; Dan Gillen; Anthony J Bleyer; Calvin Hirsch; David Siscovick; Anne B Newman Journal: J Am Soc Nephrol Date: 2005-10-26 Impact factor: 10.121
Authors: Gary L Myers; W Greg Miller; Josef Coresh; James Fleming; Neil Greenberg; Tom Greene; Thomas Hostetter; Andrew S Levey; Mauro Panteghini; Michael Welch; John H Eckfeldt Journal: Clin Chem Date: 2005-12-06 Impact factor: 8.327
Authors: Mark J Sarnak; Ronit Katz; Catherine O Stehman-Breen; Linda F Fried; Nancy Swords Jenny; Bruce M Psaty; Anne B Newman; David Siscovick; Michael G Shlipak Journal: Ann Intern Med Date: 2005-04-05 Impact factor: 25.391
Authors: Michael G Shlipak; Mark J Sarnak; Ronit Katz; Linda F Fried; Stephen L Seliger; Anne B Newman; David S Siscovick; Catherine Stehman-Breen Journal: N Engl J Med Date: 2005-05-19 Impact factor: 91.245
Authors: Yuen-Ting Diana Kwong; Lesley A Stevens; Elizabeth Selvin; Yaping Lucy Zhang; Tom Greene; Frederick Van Lente; Andrew S Levey; Josef Coresh Journal: Am J Kidney Dis Date: 2010-07 Impact factor: 8.860
Authors: Meda E Pavkov; William C Knowler; Kevin V Lemley; Clinton C Mason; Bryan D Myers; Robert G Nelson Journal: Clin J Am Soc Nephrol Date: 2011-11-10 Impact factor: 8.237
Authors: Meredith C Foster; Shih-Jen Hwang; Stacy A Porter; Joseph M Massaro; Udo Hoffmann; Caroline S Fox Journal: Hypertension Date: 2011-09-19 Impact factor: 10.190
Authors: Bryan Kestenbaum; Ronit Katz; Ian de Boer; Andy Hoofnagle; Mark J Sarnak; Michael G Shlipak; Nancy S Jenny; David S Siscovick Journal: J Am Coll Cardiol Date: 2011-09-27 Impact factor: 24.094
Authors: Shani Shastri; Hocine Tighiouart; Ronit Katz; Dena E Rifkin; Linda F Fried; Michael G Shlipak; Anne B Newman; Mark J Sarnak Journal: Clin J Am Soc Nephrol Date: 2011-04-21 Impact factor: 8.237
Authors: Kathryn A Britton; Kenneth J Mukamal; Joachim H Ix; David S Siscovick; Anne B Newman; Ian H de Boer; Evan L Thacker; Mary L Biggs; J Michael Gaziano; Luc Djoussé Journal: Vasc Med Date: 2012-03-08 Impact factor: 3.239
Authors: Pranav S Garimella; Joachim H Ix; Ronit Katz; Michel B Chonchol; Bryan R Kestenbaum; Ian H de Boer; David S Siscovick; Shani Shastri; Jade S Hiramoto; Michael G Shlipak; Mark J Sarnak Journal: Atherosclerosis Date: 2014-01-04 Impact factor: 5.162